Companies Cryptocurrencies
Celldex Therapeutics Inc
Celldex Therapeutics Inc
Exchange: Nasdaq Global Select
IPO Date: 15/05/1986
CEO: Mr. Anthony Marucci
Biotechnology Healthcare 🔗
  • CLDX
  • 30.07
  • 1405901824
    market cap
  • 0.7399998
If you bought

shares of Celldex Therapeutics Inc (CLDX) on
You would have made
Old Price $12 Current Price $12

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 137 full-time employees. The firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The company includes a multi-faceted tumor-associated macrophage (TAM) program. The firm’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Address: 53 Frontage Rd Ste 220 Hampton NEW JERSEY 08827

Stay updated.